Pancreatic Cancer Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - FibroGen, OSE Immunotherapeutics, Panbela Therapeutics, Lokon Pharma, Helix Biopharma, Tvardi Therapeutics, BioNTech, XBiotech, Lumicell, CARsgen Ther
09. Juli 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 09, 2024 (GLOBE NEWSWIRE) -- Pancreatic Cancer Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - FibroGen, OSE Immunotherapeutics, Panbela Therapeutics,...
Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
14. März 2024 08:15 ET
|
Autonomix Medical, Inc.
First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 14, 2024 (GLOBE NEWSWIRE) --...
Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
06. März 2024 08:00 ET
|
Autonomix Medical, Inc.
First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 06, 2024 (GLOBE NEWSWIRE) --...
Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial
29. Februar 2024 08:30 ET
|
Autonomix Medical, Inc.
Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Agreements represent final steps needed in order to commence...
Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study
22. Februar 2024 08:00 ET
|
Autonomix Medical, Inc.
Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Company expects to commence patient enrollment imminently...
Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
16. Februar 2024 08:00 ET
|
Autonomix Medical, Inc.
Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, Feb. ...
Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones
14. Februar 2024 08:05 ET
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to commence first study ever to evaluate...
Pancreatic Cancer Market revenue to reach USD 36 Billion by 2036, says Research Nester
29. November 2023 05:30 ET
|
Research Nester
New York, Nov. 29, 2023 (GLOBE NEWSWIRE) -- The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036. The market is poised to garner a revenue of USD 36...
Pancreatic Cancer Market to Surpass USD 7,400 Million by 2032
14. August 2023 11:57 ET
|
Precedence Research
Ottawa, Aug. 14, 2023 (GLOBE NEWSWIRE) -- The global pancreatic cancer market revenue is projected to reach around USD 5,040 million by 2029, a study published by Towards Healthcare a sister firm of...
Pancreatic Cancer Market Size Will Expand to USD 7.40 BN by 2032
04. Juli 2023 11:21 ET
|
Precedence Research
Ottawa, July 04, 2023 (GLOBE NEWSWIRE) -- The pancreatic cancer market was valued at USD 2.05 billion in 2022. Globally, the pancreatic cancer market is increasing due to rising cancer prevalence,...